Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to develop a pharmacokinetic (PK) and a
pharmacokinetic-pharmacodynamic (PK-PD) model for gabapentin in patients with neuropathic
pain.
The secondary objectives are to investigate whether adjuvant therapy of venlafaxine or
donepezil contributes to 1) improved analgesic efficacy and 2) improved health-related
quality of life (assessed by the SF-36 questionnaire) in neuropathic pain patients treated
with gabapentin.